| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MT2 |
| Uniprot No | P02795 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-59aa |
| 氨基酸序列 | MDPNCSCAAGDSCTCAGSCKCKECKCTSCKKSCCSCCPVGCAKCAQGCICKGASDKCSC |
| 预测分子量 | 7.9kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是为您模拟的3篇与MT2重组蛋白相关的参考文献示例(注：文献信息为虚构，仅供格式参考)：
1. **《Expression and Purification of Recombinant MT2 Protein in E. coli》**
- 作者：Zhang L, et al.
- 摘要：研究通过大肠杆菌表达系统高效表达MT2重组蛋白，优化诱导条件并利用镍柱亲和层析纯化，获得高纯度蛋白用于后续功能研究。
2. **《Structural and Functional Analysis of MT2 in Oxidative Stress Response》**
- 作者：Kim S, Park JH.
- 摘要：解析MT2重组蛋白的晶体结构，证实其通过螯合重金属离子和清除自由基的机制参与细胞氧化应激保护，为神经退行性疾病研究提供依据。
3. **《MT2 Recombinant Protein Attenuates Inflammation in Murine Sepsis Model》**
- 作者：Wang Y, et al.
- 摘要：在小鼠脓毒症模型中验证MT2重组蛋白的抗炎作用，发现其通过抑制NF-κB通路减少促炎因子释放，提示潜在临床治疗价值。
**建议**：实际文献请通过PubMed、Web of Science等平台检索关键词(如"MT2 recombinant protein" "metallothionein-2 expression")，可重点关注《Protein Expression and Purification》《Biochemical Journal》等期刊的相关研究。
**Background of MT2 Recombinant Protein**
MT2 (Metallothionein-2) is a small, cysteine-rich protein that plays a critical role in metal ion homeostasis, detoxification, and cellular protection against oxidative stress. Belonging to the metallothionein family, MT2 is highly conserved across species and is primarily involved in binding essential (e.g., zinc, copper) and toxic (e.g., cadmium, mercury) heavy metals through its thiol groups. This metal-binding capacity enables MT2 to regulate metal distribution, scavenge reactive oxygen species (ROS), and mitigate metal-induced toxicity.
The recombinant MT2 protein is produced via genetic engineering techniques, typically by expressing the MT2 gene in bacterial (e.g., *E. coli*) or mammalian host systems. Recombinant production allows for high-yield, scalable synthesis of the protein with consistent purity and functionality, overcoming limitations associated with isolating MT2 from natural sources. Advanced purification methods, such as affinity chromatography, ensure the removal of host contaminants, making recombinant MT2 suitable for research and therapeutic applications.
MT2 has garnered attention in biomedical research due to its dual role in metal metabolism and oxidative stress response. Studies highlight its potential in treating metal overload disorders (e.g., Wilson’s disease), neurodegenerative diseases (e.g., Alzheimer’s), and cancers where metal dysregulation or oxidative damage is implicated. Additionally, MT2’s antioxidant properties are being explored in skincare and anti-aging formulations.
Despite its promise, challenges remain in understanding tissue-specific isoforms, post-translational modifications, and interactions with other cellular components. Ongoing research aims to elucidate MT2’s regulatory mechanisms and optimize recombinant production for clinical translation. As a versatile tool, recombinant MT2 continues to bridge gaps between molecular biology, toxicology, and therapeutic development.
×
